Evidence map›Paper›PMID 25720763›Full record

Trial reportPediatric diabetes2016

Changes in beta cell function during the proximate post-diagnosis period in persons with type 1 diabetes.

Linda A DiMeglio, Peiyao Cheng, Roy W Beck, Craig Kollman, Katrina J Ruedy, Robert Slover, Tandy Aye, Stuart A Weinzimer, Andrew A Bremer, Bruce Buckingham and 1 more

Abstract readRandomized Controlled Trial
In one paragraph

Trial report in Pediatric diabetes, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
1.2field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 13 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 6 institutions in 1 country.

Linda A DiMeglioDepartment of Pediatrics, Section of Pediatric Endocrinology/Diabetology, Indiana University, Riley Hospital for Children, Indianapolis, IN, USA.
Peiyao ChengJaeb Center for Health Research, Tampa, FL, USA.
Roy W BeckJaeb Center for Health Research, Tampa, FL, USA.
Craig KollmanJaeb Center for Health Research, Tampa, FL, USA.
Katrina J RuedyJaeb Center for Health Research, Tampa, FL, USA.
Robert SloverBarbara Davis Center for Childhood Diabetes, University of Colorado School of Medicine, Aurora, CO, USA.
Tandy AyePediatric Endocrinology, Stanford University, Stanford, CA, USA.
Stuart A WeinzimerPediatric Endocrinology, Yale University, New Haven, CT, USA.
Andrew A BremerDivision of Pediatric Endocrinology, Vanderbilt University Medical Center, Nashville, TN, USA.
Bruce BuckinghamPediatric Endocrinology, Stanford University, Stanford, CA, USA.
Diabetes Research in Children Network (DirecNet); Type 1 Diabetes TrialNet Study Group
Jaeb Center for Health Research · USStanford University · USIndiana University – Purdue University Indianapolis · USUniversity of Colorado Denver · USVanderbilt University Medical Center · USYale University · US

Funding

Cooperative Multicenter Diabetes Research Network for Hypoglycemia PreventionU10HD041890 · NICHD · JAEB CENTER FOR HEALTH RESEARCH, INC. · PI BECK, ROY W. · 2007 to 2011
$9.7M
Type I Diabetes Trialnet at StsnfordU01DK061042 · NIDDK · STANFORD UNIVERSITY · PI WILSON, DARRELL M · 2001 to 2018
$8.5M
UCSF Trialnet: A Phase II Trial of Imatimib in New Onset Type I DiabetesU01DK061010 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI GITELMAN, STEPHEN E · 2001 to 2018
$8.1M
Type 1 Diabetes-A Proposal for Prevention & InterventionU01DK085476 · NIDDK · UNIVERSITY OF MINNESOTA · PI MORAN, ANTOINETTE M. · 2009 to 2018
$7.1M
Prediction and Prevention of Type I DiabetesU01DK061058 · NIDDK · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI BECKER, DOROTHY J · 2001 to 2018
$6.5M
TrialNet: Diabetes Type 1 PreventionU01DK085509 · NIDDK · UNIVERSITY OF COLORADO DENVER · PI GOTTLIEB, PETER A · 2009 to 2018
$5.8M
Vanderbilt University: Clinical Center Application, Type 1 Diabetes TrialNetU01DK085465 · NIDDK · VANDERBILT UNIVERSITY MEDICAL CENTER · PI RUSSELL, WILLIAM E · 2009 to 2018
$4.8M
Coordinating Center: Glucose Sensors in Type I DiabetesU01HD041890 · NICHD · JAEB CENTER FOR HEALTH RESEARCH, INC. · PI BECK, ROY W · 2001 to 2006
$4.1M
Yale Study of Closed-Loop Automated Glucose Control for Hypoglycemia PreventionU10HD041906 · NICHD · YALE UNIVERSITY · PI WEINZIMER, STUART ALAN · 2001 to 2011
$3.6M
Prevention of Nocturnal Hypoglycemia: Effect on Neurologic Outcome in ToddlersU10HD041908 · NICHD · STANFORD UNIVERSITY · PI BUCKINGHAM, BRUCE A · 2001 to 2011
$3.5M
Type 1 Diabetes TrialNet: Clinical Center at Yale University (U01)U01DK085466 · NIDDK · YALE UNIVERSITY · PI HEROLD, KEVAN C · 2009 to 2018
$3.3M
Type 1 Diabetes TrialNet at Indiana University Clinical CenterU01DK085505 · NIDDK · INDIANA UNIVERSITY INDIANAPOLIS · PI DIMEGLIO, LINDA A · 2009 to 2013
$3.0M
NICHD NIH HHS U01 HD041890NICHD NIH HHS U10 HD041890NICHD NIH HHS U10 HD041906NICHD NIH HHS U10 HD041908NIDDK NIH HHS U01 DK061010NIDDK NIH HHS U01 DK061042NIDDK NIH HHS U01 DK061058NIDDK NIH HHS U01 DK085465NIDDK NIH HHS U01 DK085466NIDDK NIH HHS U01 DK085476NIDDK NIH HHS U01 DK085505NIDDK NIH HHS U01 DK085509NIDDK NIH HHS U01 DK103153NIDDK NIH HHS U01 DK106984NIDDK NIH HHS U01 DK107014
6 · The paper itself

Abstract

objectivePrior studies examining beta-cell preservation in type 1 diabetes have predominantly assessed stimulated C-peptide concentrations approximately 10 wk after diagnosis. We examined whether earlier assessments might aid in prediction of beta cell function over time.

methodsUsing data from a multi-center randomized trial assessing the effect of intensive diabetes management initiated within 1 wk of diagnosis, we assessed which clinical factors predicted 90-min mixed-meal tolerance test (MMTT) stimulated C-peptide values obtained 2 and 6 wk after diagnosis. We also studied associations of these factors with C-peptide values at 1- and 2-year post-diagnosis. Data from intervention and control groups were pooled.

resultsAmong 67 study participants (mean age 13.3 ± 5.7 yr, range 7.8-45.7 yr) in multivariable analyses, C-peptide increased from baseline to 2 wks and then 6 wk. C-peptide levels at these times were significantly correlated with 1- and 2-yr C-peptide concentrations (all p < 0.001), with the strongest observed associations between 6-wk C-peptide and the 1- and 2-yr values (r = 0.66 and r = 0.61, respectively). In multivariable analyses, greater baseline and 6-wk C-peptide, and older age independently predicted greater 1- and 2-yr C-peptide concentrations.

conclusionsC-peptide assessments close to diagnosis were predictive of subsequent C-peptide production. Our data demonstrate a clear increase in C-peptide over the initial 6 wk after diabetes diagnosis followed by a plateau. Our data do not suggest that MMTT assessments performed closer to diagnosis than 6 wk would improve prediction of subsequent residual beta cell function.

Indexed as

AdolescentAdultChildC-PeptideDiabetes Mellitus, Type 1HumansInsulin-Secreting CellsMiddle AgedYoung AdultC-Peptideclinical sciencediabetes in childhoodinsulin secretions in vivo

Identifiers

PMID25720763
PMCPMC4551616
OpenAlexW1594114308

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.